FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2026
iSpecimen Inc. filed its quarterly report for the period ended March 31, 2026, reporting a net loss of $2.3 million for the three months ended March 31, 2026, compared to a net loss of $1.9 million for the same period in 2025. The company’s total revenue increased by 15% to $1.4 million, driven by growth in its specimen management and logistics business. The company’s cash and cash equivalents decreased by $1.1 million to $3.4 million, primarily due to the use of cash for operating activities. The company’s total assets increased by 12% to $6.3 million, primarily due to the increase in accounts receivable and inventory. The company’s total liabilities increased by 10% to $2.5 million, primarily due to the increase in accounts payable and accrued expenses.
Overview
iSpecimen is a company that operates a global marketplace platform called the iSpecimen Marketplace, which connects researchers to subjects, specimens, and associated data to accelerate life science research and development. The company was incorporated in 2009 and is headquartered in Woburn, Massachusetts.
The iSpecimen Marketplace automates the process of searching for and selecting specimens for research. It taps into healthcare provider data to gain insights into available samples in biobanks or laboratories, or to gain insights into patient populations to support specimen collections directly from research subjects. Researchers can use the platform to efficiently find and request the specific specimens they need for their studies, while biospecimen providers can access the platform to manage their specimen supply and fulfillment workflows.
Revenue and Profit Trends
- Revenue decreased by 85% from $1.06 million in Q1 2025 to $156,000 in Q1 2026, primarily due to a 61% decrease in specimen count.
- The average selling price per specimen decreased by 62% from $458 in Q1 2025 to $175 in Q1 2026.
- Cost of revenue decreased by 87% from $657,000 in Q1 2025 to $84,000 in Q1 2026, due to the decrease in specimens delivered.
- The company experienced a net loss of $2.28 million in Q1 2026, compared to a net loss of $1.58 million in Q1 2025.
Strengths and Weaknesses
Strengths:
- Proprietary technology platform that automates the specimen procurement process
- Established network of biospecimen providers
- Ability to gain insights into available samples and patient populations
Weaknesses:
- Significant decline in revenue and specimen volume in recent quarters
- Ongoing net losses and cash burn
- Reliance on a small number of customers and suppliers
Outlook
The company’s financial performance has been negatively impacted by the current economic conditions, including decreased customer demand and procurement of specimens. To address these challenges, the company has taken steps to reduce costs, including workforce reductions and streamlining operations.
The company believes its business will continue to be resilient through an economic slowdown, and it is working to improve its liquidity and alleviate adverse effects on its business. However, the company has expressed substantial doubt about its ability to continue as a going concern, and its future success will depend on its ability to generate additional revenue, contain operating costs, and potentially raise additional capital.
The company’s strategic initiatives, including a sales overhaul, enhanced business intelligence, and a focus on its core competencies, are aimed at driving growth and improving its financial position. However, the company’s ability to execute on these plans and the long-term implications of the ongoing Russian-Ukrainian war remain uncertain.
